Survival analysis
From Jan. 2009 to June 2018, no patient died from endometrial cancer with follow-up, 7 (1.8%) patients had recurrence (Table 5). 5-year overall survival was 100.0% and 5-year progression survival was 98.2% (7/381). Kaplan-Meier curves showed grade 3 patients were not associated with shorter overall survival or progression free survival compared with grade 1&2 group (logrank p>0.05) (Figure 2). In EEC G3 patients at stage I or II, overall survival and progression free survival analysis showed no distinct difference of two subgroups: The first was divided into chemotherapy, radiotherapy and chemoradiotherapy (log rank p>0.05); the second was classified as pelvic LND (PVLND) and pelvic + para aortic LND (PV+PALND) (log rank p>0.05) (Figure 3).